Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

GOSH TvT CAR7 Phase I: Positive trial results with CRISPR base-edited CAR-T cells is a significant step in treating cancer, says GlobalData

Following the news that the first patient in the UCL Great Ormond Street Insititute of Child Health’s (GOSH) Phase I TvT CAR7 trial to treat pediatric relapsed/refractory T-cell acute lymphoblastic leukemia, has gone into remission; James Donagher, Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “While the GOSH […]
Read more

Potential prophylactic antibiotic use for Strep A infections highlights need for vaccine, says GlobalData

Following the news that, amid rising cases and deaths nationally, antibiotics could be administered prophylactically in UK schools with cases of streptococcus A (Strep A); Fiona Chisholm, Associate Director at GlobalData, a leading data and analytics company, offers her view: “Health officials are under increased pressure to curb inappropriate use of antibiotics and rarely give […]
Read more

Merck’s Imago Biosciences acquisition to go head-to-head with GSK in increasingly competitive blockbuster market, says GlobalData

Following the news that Merck is to acquire Imago Biosciences, a clinical-stage biotech developing the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for the treatment of myelofibrosis (MF); Sam Warburton, Oncology Analyst at GlobalData, a leading data and analytics company, offers his view: “Big pharma appears to be setting its sights on the relatively small but potentially […]
Read more

Cannabinoid-based drug developers face challenging regulatory landscape despite increasing use of cannabinoid receptors, says GlobalData

A surge in the cannabinoid drug pipeline has led to cannabinoid receptors becoming the most popular target in preclinical development this year, says GlobalData. However, the leading data and analytics company notes that the current regulatory landscape poses a challenge for cannabinoid-based drug developers and regulators. CB1 receptors are the joint first most popular target in […]
Read more

Technology partnerships around genomic profiling to drive cancer care towards precision medicine in India, says GlobalData

As cancer treatment is evolving globally, the regular approach of one-size-fits-all is being challenged with precision medicine, a concept that involves genetic screening of the patient to allow doctors to select an appropriate treatment for a better outcome. In this context, the recent alliances forged around the development of genomic profiling tests in India are […]
Read more

Fierce competition anticipated in DLBCL setting as novel therapeutics from multiple classes fill pipeline, says GlobalData

Significant changes in the treatment landscape of diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin’s lymphoma, has led to an explosion of research and development in this disease setting, says GlobalData. According to the leading data and analytics company, there are over 255 products currently in clinical trials for the treatment […]
Read more

mRNA non-vaccine therapeutics set to reach $2 billion in sales by 2028 driven by approval of pipeline agents, forecasts GlobalData

There are currently no messenger RNA (mRNA) non-vaccine therapeutics on the market. However, this landscape will reach a total of five marketed products by 2028, generating over $2 billion in revenue across the seven major markets (7MM*), says GlobalData, a leading data and analytics company. According to GlobalData’s recent report, ‘mRNA Therapeutics – Thematic Intelligence’, […]
Read more

Positive results for Luye Pharma schizophrenia drug LY03010, but faces a crowded market, says GlobalData

Luye Pharma’s pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated comparable bioavailability with Johnson and Johnson’s Invega Sustenna at steady state. If approved, it will create more options for the management of schizophrenia, but will have to face a crowded LAI […]
Read more

39% of healthcare industry professionals expect investment in emerging technologies to decrease due to inflation and rising costs, finds GlobalData

According to a GlobalData survey, 39% of healthcare industry professionals globally expect to see a decrease in the amount that is being invested in emerging technologies over the next 12 months due to current economic conditions. The survey, which was published in the leading data and analytics company’s latest report, ‘Digital Transformation and Emerging Technology […]
Read more

NICE endometriosis guideline update is a positive step for diagnosis and surgical management, says GlobalData

Following the news that the National Institute of Health and Care Excellence (NICE) has agreed to update its guidelines on endometriosis diagnosis and surgical management when fertility is a priority; Amy Murray, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “The updated NICE guidelines on endometriosis marks the first such […]
Read more

Lumos Pharma’s oral LUM-201 holds potential to improve compliance in pediatric growth hormone deficiency, says GlobalData

The release of encouraging interim results from two Phase II trials of LUM-201 has enabled Lumos Pharma to edge closer towards its goal of bringing the first orally administered therapy for pediatric growth hormone deficiency (PGHD) to market. With a favorable administration route, LUM-201 has the potential to improve low rates of treatment compliance, a […]
Read more

Sotatercept set to become leading therapy in PAH market, says GlobalData

Following the news that Merck reported positive top-line Phase III clinical trial results for its pulmonary arterial hypertension (PAH) pipeline drug, sotatercept; Kaya Olczak, Healthcare Analyst at GlobalData, a leading data and analytics company, comments: “Sotatercept has potential to fulfil a highly unmet need in the PAH space: the lack of a disease modifying therapy. […]
Read more

Arcutis’s roflumilast estimated to bring $80 million in sales by 2030 following promising clinical trial results, says GlobalData

Following the news that Arcutis Biotherapeutics announced that its roflumilast met its main endpoints in the Phase III trial INTEGUMENT-1 (NCT04773587) for atopic dermatitis (AD). Ramla Salad, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Following such a fantastic result, GlobalData expects Arcutis Biotherapeutics’ roflumilast to enter the US atopic […]
Read more

CAR-T therapy shows huge promise for treating CLL, but significant clinical challenges remain, says GlobalData

Despite a number of barriers and complications for autologous agents, there are a total 44 CAR-T* therapies in the pipeline for chronic lymphocytic leukemia (CLL), says GlobalData. Autologous CAR-T therapy is a patient-specific immunotherapy that involves the genetic modification of a patient’s own T cells to attack their cancer. However, this therapy is typically less […]
Read more

ABPP amyloid plaques’ role in onset of Alzheimer’s questioned by Cincinnati University: GlobalData reveals that ABPP targeted by a tenth of all Alzheimer’s drugs

One of the leading theories for the cause of Alzheimer’s disease (AD) is the collection of abnormal amyloid plaques, a collection of misfolded amyloid A4 beta proteins (ABPP) that form in the spaces between nerve cells in the brain. This has led to a significant focus on producing drugs that inhibit ABPP, with leading data and […]
Read more

Roche’s gantenerumab Alzheimer’s disease failure will boost prospects for Eisai and Biogen’s lecanemab, says GlobalData

Following the news that Roche’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), gantenerumab failed to significantly slow clinical decline in patients with early Alzheimer’s disease (AD) in two Phase III clinical trials, GRADUATE I and II (NCT03443973 and NCT03444870); Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Gantenerumab’s […]
Read more

Novo Nordisk likely to maintain lead against competitor Eli Lilly in global T2D market, says GlobalData

Despite plagued with supply issues over the past one year, Novo Nordisk’s glucagon-like peptide-1 (GLP-1) franchise—including Rybelsus, Saxenda, Ozempic, and Wegovy—enjoyed a strong performance. Against this backdrop, the Denmark-based pharmaceutical company is poised to maintain a strong market position against competitor Eli Lilly in the type 2 diabetes (T2D) market, says GlobalData, a leading data […]
Read more

The treatment of atopic dermatitis could be improved by new anti-itch agents in development, says GlobalData

Anti-itch agents are becoming more prominent in the atopic dermatitis (AD) therapeutic space as pruritis (itchy skin) is an integral symptom, affecting all patients regardless of age and disease severity. As a result, there are multiple new product candidates in the early and late-stage pipeline, finds GlobalData, a leading data and analytics company. Cara Therapeutics […]
Read more
1 … 40 41 42 43 44 … 108